Patents by Inventor Scott Bowersox

Scott Bowersox has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250032442
    Abstract: The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to enhance one or more cognitive function and to treat one or more cognitive impairment.
    Type: Application
    Filed: November 16, 2022
    Publication date: January 30, 2025
    Inventors: Scott BOWERSOX, Nalina DRONAMRAJU, Wayne MACFADDEN, Eileen LEARY
  • Publication number: 20040006036
    Abstract: The invention provides methods and compositions related to oligonucleotides that silence target genes within a cell. The oligonucleotides include an oligonucleotide methylator segment that has a first strand and a second strand complementary to the first strand. The first strand can include at least one m5CG sequence which is paired with an unmethylated CG sequence on the second strand. Alternatively, the first strand can include at least one m5CNIG sequence paired with an unmethylated CN2G sequence on the second strand, wherein N1 is any nucleotide, and N2 is a nucleotide that pairs with N1. The oligonucleotides also include a single-stranded DNA binding segment that is complementary to a nucleotide sequence in the target gene. The DNA binding segment includes at least one m5CG sequence m5CG or at least one 5CN3G sequence, wherein N3 is any nucleotide.
    Type: Application
    Filed: April 22, 2003
    Publication date: January 8, 2004
    Applicant: GMR, a Delaware corporation
    Inventors: Ji-Fan Hu, Scott Bowersox
  • Patent number: 6653460
    Abstract: A novel class of peptides selectively block class E voltage-gated calcium channels. The class is exemplified by HG peptides such as HG-1, which is isolated from the venom-producing cells of the tarantula Hysterocrates gigas. Also disclosed are methods of producing blocking class E channels using the peptides. HG peptides have utility, for example, in inhibiting oxytocin release and for use as anticonvulsants.
    Type: Grant
    Filed: August 16, 2000
    Date of Patent: November 25, 2003
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Robert Newcomb, Andrew L. Palma, Balazs G. Szoke, Katalin Tarczy-Hornoch, William F. Hopkins, Ruth L. Cong, George P. Miljanich, Robin Dean, Laszlo Nadasdi, Laszlo Urge, Stephen Scott Bowersox
  • Patent number: 6156726
    Abstract: A novel class of peptides selectively block class E voltage-gated calcium channels. The class is exemplified by HG peptides such as HG-1, which is isolated from the venom-producing cells of the tarantula Hysterocrates gigas. Also disclosed are methods of producing blocking class E channels using the peptides. HG peptides have utility, for example, in inhibiting oxytocin release and for use as anticonvulsants.
    Type: Grant
    Filed: August 1, 1997
    Date of Patent: December 5, 2000
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Robert Newcomb, Andrew L. Palma, Balazs G. Szoke, Katalin Tarczy-Hornoch, William F. Hopkins, Ruth L. Cong, George P. Miljanich, Robin Dean, Laszlo Nadasdi, Laszlo Urge, Stephen Scott Bowersox
  • Patent number: 6140484
    Abstract: Bax-.omega. polynucleotides and polypeptides, and compositions effective to hybridize to Bax-.omega. polynucleotides are disclosed. Also disclosed are methods for altering apoptosis in cells, for promoting cell survival and for identifying compounds capable of affecting the binding of Bax-.omega. to other proteins involved in apoptosis.
    Type: Grant
    Filed: March 10, 1998
    Date of Patent: October 31, 2000
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Catherine Mastroni Bitler, Stephen Scott Bowersox, Roberto Crea, Susan Dunham Demo, William A. Horne, Mei Zhou
  • Patent number: 6054429
    Abstract: A improved method of treating pain is disclosed. The method includes administering to a subject an N-type voltage-sensitive calcium channel blocking omega conopeptide which is characterized by its ability to (a) inhibit electrically stimulated contraction of the guinea pig ileum, and (b) bind selectively to omega conopeptide MVIIA binding sites present in neuronal tissue. The method includes administering the omega conopeptide epidurally, preferably so that the compound is in prolonged or sustained contact with the epidural region.
    Type: Grant
    Filed: March 8, 1996
    Date of Patent: April 25, 2000
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: S. Scott Bowersox, Theresa Gadbois, Mark Raymond Pettus, Robert R. Luther
  • Patent number: 5891849
    Abstract: A method of preventing progression of neuropathic pain is disclosed. The method includes administering to a subject an N-type voltage-sensitive calcium channel blocking compound which is characterized by its ability to (a) inhibit electrically stimulated contraction of the guinea pig ileum, and (b) bind selectively to omega conopeptide MVIIA binding sites present in neuronal tissue. Also disclosed are formulations effective to stabilize omega conotoxin peptide preparations at elevated temperatures. Novel omega conopeptides also form part of the invention.
    Type: Grant
    Filed: November 7, 1997
    Date of Patent: April 6, 1999
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Gary Arthur Amstutz, Stephen Scott Bowersox, Kishorchandra Gohil, Peter Isadore Adriaenssens, Ramasharma Kristipati
  • Patent number: 5795864
    Abstract: Disclosed are formulations effective to stabilize omega conotoxin peptide preparations at elevated temperatures. Novel omega conopeptides also form part of the invention.
    Type: Grant
    Filed: June 27, 1995
    Date of Patent: August 18, 1998
    Assignee: Neurex Corporation
    Inventors: Gary Arthur Amstutz, Stephen Scott Bowersox, Kishorchandra Gohil, Peter Isadore Adriaenssens, Ramasharma Kristipati
  • Patent number: 5770690
    Abstract: Bax-.omega. polynucleotides and polypeptides, and compositions effective to hybridize to Bax-.omega. polynucleotides are disclosed. Also disclosed are methods for altering apoptosis in cells, for promoting cell survival and for identifying compounds capable of affecting the binding of Bax-.omega. to other proteins involved in apoptosis.
    Type: Grant
    Filed: March 15, 1996
    Date of Patent: June 23, 1998
    Assignee: Neurex Corporation
    Inventors: Catherine Mastroni Bitler, Stephen Scott Bowersox, Roberto Crea, Susan Dunham Demo, William A. Horne, Mei Zhou